Nicoletto, Rachel E.
Holdcraft, Cayla J.
Yin, Ariel C.
Retzbach, Edward P.
Sheehan, Stephanie A.
Greenspan, Amanda A.
Laugier, Christopher M.
Trama, Jason
Zhao, Caifeng
Zheng, Haiyan
Goldberg, Gary S.
Article History
Received: 6 March 2024
Accepted: 4 October 2024
First Online: 13 October 2024
Competing interests
: GSG has intellectual property and ownership in Sentrimed, Inc., and REN, CH, and ACY received financial support from Sentrimed, Inc. which is developing agents that target Pdpn to treat diseases including cancer and arthritis. The remaining authors declare no conflicts of interest.